264 related articles for article (PubMed ID: 28950886)
1. HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus.
Kim YY; Park KT; Jang SY; Lee KH; Byun JY; Suh KH; Lee YM; Kim YH; Hwang KW
Arthritis Res Ther; 2017 Sep; 19(1):211. PubMed ID: 28950886
[TBL] [Abstract][Full Text] [Related]
2. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
[TBL] [Abstract][Full Text] [Related]
3. Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase.
Mina-Osorio P; LaStant J; Keirstead N; Whittard T; Ayala J; Stefanova S; Garrido R; Dimaano N; Hilton H; Giron M; Lau KY; Hang J; Postelnek J; Kim Y; Min S; Patel A; Woods J; Ramanujam M; DeMartino J; Narula S; Xu D
Arthritis Rheum; 2013 Sep; 65(9):2380-91. PubMed ID: 23754328
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis.
Rankin AL; Seth N; Keegan S; Andreyeva T; Cook TA; Edmonds J; Mathialagan N; Benson MJ; Syed J; Zhan Y; Benoit SE; Miyashiro JS; Wood N; Mohan S; Peeva E; Ramaiah SK; Messing D; Homer BL; Dunussi-Joannopoulos K; Nickerson-Nutter CL; Schnute ME; Douhan J
J Immunol; 2013 Nov; 191(9):4540-50. PubMed ID: 24068666
[TBL] [Abstract][Full Text] [Related]
5. Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.
Chalmers SA; Wen J; Doerner J; Stock A; Cuda CM; Makinde HM; Perlman H; Bosanac T; Webb D; Nabozny G; Fine JS; Klein E; Ramanujam M; Putterman C
Arthritis Res Ther; 2018 Jan; 20(1):10. PubMed ID: 29370834
[TBL] [Abstract][Full Text] [Related]
6. HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis.
Park JK; Byun JY; Park JA; Kim YY; Lee YJ; Oh JI; Jang SY; Kim YH; Song YW; Son J; Suh KH; Lee YM; Lee EB
Arthritis Res Ther; 2016 Apr; 18():91. PubMed ID: 27090981
[TBL] [Abstract][Full Text] [Related]
7. A benzenediamine derivative fc-99 attenuates lupus-like syndrome in MRL/lpr mice related to suppression of pDC activation.
Ji J; Fan H; Li F; Li X; Dong G; Gong W; Song Y; Liu F; Hua C; Tan R; Dou H; Hou Y
Immunol Lett; 2015 Dec; 168(2):355-65. PubMed ID: 26545567
[TBL] [Abstract][Full Text] [Related]
8. Btk inhibition treats TLR7/IFN driven murine lupus.
Bender AT; Pereira A; Fu K; Samy E; Wu Y; Liu-Bujalski L; Caldwell R; Chen YY; Tian H; Morandi F; Head J; Koehler U; Genest M; Okitsu SL; Xu D; Grenningloh R
Clin Immunol; 2016 Mar; 164():65-77. PubMed ID: 26821304
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of FcγRIIB regulates downstream protein phosphorylation and suppresses B cell activation to ameliorate systemic lupus erythematosus.
Sheng L; Cao X; Chi S; Wu J; Xing H; Liu H; Yang Z
Int J Mol Med; 2020 Oct; 46(4):1409-1422. PubMed ID: 32945349
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of Bruton's tyrosine kinase in peripheral blood is associated with lupus nephritis.
Kong W; Deng W; Sun Y; Huang S; Zhang Z; Shi B; Chen W; Tang X; Yao G; Feng X; Sun L
Clin Rheumatol; 2018 Jan; 37(1):43-49. PubMed ID: 28612243
[TBL] [Abstract][Full Text] [Related]
11. Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFN
Katewa A; Wang Y; Hackney JA; Huang T; Suto E; Ramamoorthi N; Austin CD; Bremer M; Chen JZ; Crawford JJ; Currie KS; Blomgren P; DeVoss J; DiPaolo JA; Hau J; Johnson A; Lesch J; DeForge LE; Lin Z; Liimatta M; Lubach JW; McVay S; Modrusan Z; Nguyen A; Poon C; Wang J; Liu L; Lee WP; Wong H; Young WB; Townsend MJ; Reif K
JCI Insight; 2017 Apr; 2(7):e90111. PubMed ID: 28405610
[TBL] [Abstract][Full Text] [Related]
12. Pim-1 as a Therapeutic Target in Lupus Nephritis.
Fu R; Xia Y; Li M; Mao R; Guo C; Zhou M; Tan H; Liu M; Wang S; Yang N; Zhao J
Arthritis Rheumatol; 2019 Aug; 71(8):1308-1318. PubMed ID: 30791224
[TBL] [Abstract][Full Text] [Related]
13. A benzenediamine derivate FC-99 attenuates lupus nephritis in MRL/lpr mice via inhibiting myeloid dendritic cell-secreted BAFF.
Ji J; Xu J; Li F; Li X; Gong W; Song Y; Dou H; Hou Y
Acta Biochim Biophys Sin (Shanghai); 2016 May; 48(5):411-9. PubMed ID: 27121231
[TBL] [Abstract][Full Text] [Related]
14. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF).
Zhou L; Sun L; Wu H; Zhang L; Chen M; Liu J; Zhong R
Eur J Pharmacol; 2013 Sep; 715(1-3):230-7. PubMed ID: 23712004
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory effects of H.P. Acthar Gel on B cell development in the NZB/W F1 mouse model of systemic lupus erythematosus.
Decker DA; Grant C; Oh L; Becker PM; Young D; Jordan S
Lupus; 2014 Jul; 23(8):802-12. PubMed ID: 24759631
[TBL] [Abstract][Full Text] [Related]
16. Ophiopogonin D attenuates the progression of murine systemic lupus erythematosus by reducing B cell numbers.
Nie Y; Li C; Sun N
J Biochem Mol Toxicol; 2023 Jul; 37(7):e23361. PubMed ID: 36999444
[TBL] [Abstract][Full Text] [Related]
17. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
[TBL] [Abstract][Full Text] [Related]
18. Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus.
Ren J; Catalina MD; Eden K; Liao X; Read KA; Luo X; McMillan RP; Hulver MW; Jarpe M; Bachali P; Grammer AC; Lipsky PE; Reilly CM
Front Immunol; 2019; 10():2512. PubMed ID: 31708928
[TBL] [Abstract][Full Text] [Related]
19. Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice.
Yan SX; Deng XM; Wang QT; Sun XJ; Wei W
Acta Pharmacol Sin; 2015 Nov; 36(11):1367-76. PubMed ID: 26456588
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis.
Pohlmeyer CW; Shang C; Han P; Cui ZH; Jones RM; Clarke AS; Murray BP; Lopez DA; Newstrom DW; Inzunza MD; Matzkies FG; Currie KS; Di Paolo JA
BMC Rheumatol; 2021 Mar; 5(1):15. PubMed ID: 33781343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
